Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1404644 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $33.22Day −4.04%Mkt cap $525M1Y +53.2%Off 52W high −23.9%Vol (1Y) 83.5%
Daily closing price, split-adjusted to the current basis; 2.6y shown of 647 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest18.5% of sh out |
| Days to cover7.6d |
| 13F net flow (QoQ)+5.36% |
| Top-10 13F concentration67.2% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$98.6M |
| ROE−31.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+61.3% |
| 1Y+53.2% |
| Since incept. (ann.)+35.3% |
Total return through 2026-07-28 · series begins 2023-12-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)83.5% |
| Ann. volatility (3Y)106.4% |
| Sharpe (1Y)0.93 |
| Sharpe (3Y)0.83 |
| Max drawdown (1Y)−52.4% |
| Max drawdown (3Y)−89.7% |
| Beta (3Y vs SPY)1.89 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 1.7M | $35M | 10.87% | +0.0% |
| Redmile Group, LLC | 1.5M | $29M | 9.24% | +0.0% |
| Casdin Capital, LLC | 1.4M | $29M | 8.99% | +9.6% |
| RTW INVESTMENTS, LP | 1.4M | $27M | 8.62% | +0.0% |
| EcoR1 Capital, LLC | 1.3M | $26M | 8.05% | +0.0% |
| BlackRock, Inc. | 1.0M | $20M | 6.36% | +6.3% |
| BAKER BROS. ADVISORS LP | 991,691 | $20M | 6.28% | +0.0% |
| Trails Edge Capital Partners, LP | 782,787 | $16M | 4.95% | −0.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 107.4% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 3,720,441 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$1.39 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.99 | — | $0 | — |
| 2025-06-30 | 2025-08-11 | −$1.05 | — | $0 | −100.0% |
| 2025-03-31 | 2025-05-09 | −$1.08 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 94d) — not company-confirmed.
